Marché de l’amylose héréditaire à transthyrétine au Moyen-Orient et en Afrique – Tendances et prévisions de l’industrie jusqu’en 2030

Analyse et taille du marché de l'amylose à transthyrétine héréditaire au Moyen-Orient et en Afrique

Le marché de l'amylose à transthyrétine héréditaire au Moyen-Orient et en Afrique devrait croître au cours de l'année de prévision en raison de l'augmentation du nombre d'acteurs du marché et de la disponibilité d'appareils de diagnostic technologiques avancés. Le développement croissant dans le domaine des techniques avancées devrait en outre stimuler la croissance du marché. Cependant, des difficultés telles que les réglementations strictes pour la production et la commercialisation de médicaments de traitement et de dispositifs médicaux pour le diagnostic et la chirurgie devraient freiner la croissance du marché au cours de la période de prévision.

Data Bridge Market Research analyse que le marché de l'amylose héréditaire à transthyrétine au Moyen-Orient et en Afrique devrait atteindre la valeur de 65 985,45 milliers USD d'ici 2030, à un TCAC de 3,1 % au cours de la période de prévision. Ce rapport de marché couvre également en profondeur l'analyse des prix et les avancées technologiques.

Définition du marché

The Middle East and Africa hereditary transthyretin amyloidosis market is a pharmaceutical and biotechnology market focused on the treatment and diagnosis of hATTR, a rare genetic disease characterized by the accumulation of abnormal transthyretin protein in tissues and organs, leading to various organ dysfunctions.

Hereditary transthyretin amyloidosis (hATTR) is a rare, inherited genetic disorder characterized by the accumulation of abnormal transthyretin protein (TTR) in various tissues and organs of the body. TTR is a protein primarily produced in the liver and is responsible for transporting thyroxine (a thyroid hormone) and retinol (vitamin A) in the bloodstream. In hATTR, a genetic mutation leads to the misfolding of TTR proteins, causing them to form amyloid fibrils that deposit in organs, disrupting their normal function. There are different forms of hATTR, including hereditary ATTR polyneuropathy (hATTR-PN) and hereditary ATTR cardiomyopathy (hATTR-CM). In hATTR-PN, the peripheral nerves are primarily affected, resulting in sensory, motor, and autonomic dysfunction. Patients may experience symptoms such as numbness, tingling, muscle weakness, and gastrointestinal problems.

Middle East and Africa Hereditary Transthyretin Amyloidosis Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

• Rising Prevalence of Hereditary Transthyretin Amyloidosis

Hereditary transthyretin amyloidosis (hATTR), also known as familial amyloid polyneuropathy (FAP), is a rare and inherited disorder characterized by the abnormal accumulation of amyloid fibrils in various organs and tissues of the body. Amyloid fibrils are misfolded proteins that clump together and can lead to organ dysfunction over time.

Transthyretin (TTR) is a protein primarily produced by the liver, and its normal function is to transport thyroxine (a thyroid hormone) and retinol (a form of vitamin A) in the blood. In hATTR, a genetic mutation causes the transthyretin protein to become unstable and more likely to misfold, leading to the formation of amyloid deposits.

The prevalence of hereditary transthyretin amyloidosis (hATTR) is on the rise due to various factors. Firstly, improved genetic testing methods have made it easier and more affordable to identify individuals at risk for hATTR, leading to earlier diagnoses and a better understanding of the disease's prevalence. Increased awareness of hATTR among medical professionals and the general public has resulted in more cases being recognized and diagnosed. Better reporting and data collection lead to a more accurate estimation of the prevalence of hATTR is emerging.

Lastly, the growing aging population has likely played a role in the increasing prevalence of hATTR. This condition typically has a later onset, and as the population ages, a larger number of individuals may develop symptoms of hATTR, leading to a rise in reported cases.

• Increasing Research and Clinical Trials for Hereditary Transthyretin Amyloidosis

There is an increase in research and clinical trials focused on hereditary transthyretin amyloidosis (hATTR) for the past few years. This surge in scientific interest can be attributed to several factors, including advancements in our understanding of the disease's genetic basis and pathophysiology. Researchers have identified various mutations in the transthyretin gene associated with hATTR, and this genetic knowledge has paved the way for targeted therapies.

One of the most promising therapeutic approaches for hATTR is the use of TTR stabilizers. These medications aim to stabilize the transthyretin protein, preventing it from misfolding and forming amyloid fibrils. In clinical trials, these drugs have shown promising results in slowing disease progression and improving patients' quality of life.

Another exciting avenue of research for hATTR is gene silencing therapy, specifically RNA interference (RNAi) and antisense oligonucleotides (ASOs). These treatments work by reducing the production of abnormal transthyretin protein, thereby reducing the amount of amyloid fibrils formed. Early clinical trials have shown encouraging results, with some gene silencing therapies demonstrating significant reductions in the levels of abnormal TTR protein in the blood.

In addition to these approaches, gene editing techniques, such as CRISPR-Cas9 are being explored for their potential in treating hATTR. CRISPR-Cas9 allows scientists to precisely edit the transthyretin gene, correcting or removing the disease-causing mutations. Although still in the early stages of development, gene editing holds promise for providing a more permanent and curative solution for hATTR.

Many countries have established patient registries to support research and clinical trials, that collect data on individuals with hATTR. These registries help researchers better understand the natural history of the disease, identify potential participants for clinical trials and track treatment outcomes.

Thus increasing research and clinical trials for hereditary transthyretin amyloidosis is expected to act as a driver for market growth.

Opportunity

Government Initiatives for Hereditary Transthyretin Amyloidosis Treatment

Increasing recognition by governmental bodies for the importance of addressing hereditary transthyretin amyloidosis (hATTR) and providing better support for affected individuals. These governmental initiatives are driven by the understanding that hATTR is a rare and severe genetic disease with a significant impact on patients' lives. The initiatives aim to improve awareness, research, patient care, and access to effective treatments for hATTR.

One crucial aspect of governmental initiatives is research funding. Governments have allocated funds to support scientific research on hATTR, both at the basic science level and for clinical studies. These funds encourage scientists and medical researchers to explore the disease's underlying mechanisms, identify potential therapeutic targets, and develop novel treatment approaches. Governments contribute to advancing knowledge about hATTR and potentially finding better ways to manage and treat the disease by providing financial support to research projects.

Thus, government initiatives for hereditary transthyretin amyloidosis treatment are expected to act as opportunities for market growth.

Restraints / Challenges

• High Cost Associated with Hereditary Transthyretin Amyloidosis Treatment

The high cost associated with hereditary transthyretin amyloidosis (hATTR) treatments can be a significant barrier for patients and healthcare systems.

Several factors contribute to the elevated expenses in developing and providing these therapies. Firstly, research and development (R&D) costs are a major driver of high treatment expenses. Developing new drugs, especially for rare diseases, such as hATTR, requires substantial investments in basic research, preclinical studies, and clinical trials. The cost of identifying potential drug targets, conducting animal studies, and moving through multiple phases of clinical trials can be substantial. Moreover, the risk of failure in the early stages of drug development means that companies must recoup the costs of both successful and unsuccessful ventures, further increasing the financial burden.

Thus, the high cost associated with hereditary transthyretin amyloidosis is expected to act as a restraint for market growth.

• Complexity in Diagnosing Hereditary Transthyretin Amyloidosis

The diagnosis of complex hereditary transthyretin amyloidosis (hATTR) can be a challenging and complex process due to the diverse clinical manifestations and the rarity of the disease. hATTR is a genetically heterogeneous disorder caused by mutations in the transthyretin (TTR) gene, leading to the accumulation of abnormal TTR protein as amyloid deposits in various organs, including the peripheral nerves, heart, and gastrointestinal system.

One of the critical steps in hATTR diagnosis is genetic testing to identify the specific mutation in the TTR gene. However, there are hundreds of known TTR gene mutations, and identifying the exact mutation can be challenging, requiring specialized genetic testing and expertise. Genetic testing is especially crucial in differentiating hATTR from other forms of amyloidosis, such as wild-type ATTR (ATTRwt) and AL amyloidosis, which may have overlapping clinical features.

Thus, complex hereditary transthyretin amyloidosis diagnosis is expected to act as a challenge for market growth.

Recent Development

• In June 2022, Alnylam Pharmaceuticals, Inc. received FDA authorization for AMVUTTRA (vutrisiran) for the treatment of Polyneuropathy of hereditary transthyretin-mediated amyloidosis.
• In April 2023, Canon Medical Systems Corporation announced that it had  begun clinical research by employing a next-generation X-ray CT system with photon counting computed tomography with the National Cancer Center Japan (NCC) . This will help the organization in developing its products category.
• In December 2022, a new technology AIR Recon DL was recently recognized in the “Best of What's New” awards by Popular Science magazine. It is a new technique developed by GE Healthcare for delivering high-quality images in a short amount of time. AIR Recon DL uses deep-learning technology to simultaneously improve MRI image quality and enable reduced scan time, improving the patient experience.

Middle East and Africa Hereditary Transthyretin Amyloidosis Market Scope

The Middle East and Africa hereditary transthyretin amyloidosis market is segmented into six notable segments, diagnosis and treatment, gene variation, gender, indication, end-user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

 Diagnosis and Treatment

• Diagnosis
• Treatment

On the basis of diagnosis and treatment, the market is segmented into diagnosis and treatment.

 Gene Variation

• V122L
• T60A
• V30M
• Others

On the basis of gene variation, the market is segmented into V122L, T60A, V30M, and others.

Gender

• Male
• Female

On the basis of gender, the market is segmented into male and female.

Indication

• Cardiomyopathy (ATTR-CM)
• Polyneuropathy (ATTR-PN)
• Mixed Indications

On the basis of indications, the market is segmented into cardiomyopathy (ATTR-CM), polyneuropathy (ATTR-PN), and mixed indications.

End User

• Hospitals and Clinics
• Diagnostic Laboratories
• Radiology Centers
• Academic and Research Institutes
• Ambulatory Surgical Centers
• Homecare

On the basis of end user, the market is segmented into hospitals and clinics, diagnostic laboratories, radiology centers, academic and research institutes, ambulatory surgical centers, and homecare.

Distribution Channel

• Direct Tender
• Third party Distributors
• Pharmacie de l'hôpital
• Pharmacie de détail
• Autres

Sur la base du canal de distribution, le marché est segmenté en appels d'offres directs, distributeurs tiers, pharmacies hospitalières, pharmacies de détail et autres.

Analyse/perspectives du marché de l'amylose à transthyrétine héréditaire au Moyen-Orient et en Afrique

Le marché de l’amylose à transthyrétine héréditaire au Moyen-Orient et en Afrique est analysé et des informations et tendances sur la taille du marché sont fournies par diagnostic et traitement, variation génétique, sexe, indication, utilisateur final et canal de distribution comme référencé ci-dessus.

Les pays couverts par le marché de l’amylose à transthyrétine héréditaire au Moyen-Orient et en Afrique sont l’Afrique du Sud, l’Arabie saoudite, les Émirats arabes unis, l’Égypte, Israël et le reste du Moyen-Orient et de l’Afrique.

L'Afrique du Sud devrait dominer le marché et connaître la croissance la plus rapide en raison de l'augmentation de la sensibilisation et de l'éducation aux maladies parmi les professionnels de la santé et le public, ce qui a probablement contribué à l'identification et à la gestion de maladies telles que l'amylose à transthyrétine héréditaire.

La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques, l'analyse des cinq forces du porteur et les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour chaque pays. En outre, la présence et la disponibilité des marques régionales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales.

Analyse du paysage concurrentiel et des parts de marché de l'amylose à transthyrétine héréditaire au Moyen-Orient et en Afrique

Le paysage concurrentiel du marché de l'amylose à transthyrétine héréditaire au Moyen-Orient et en Afrique fournit des détails sur le concurrent. Les détails inclus sont un aperçu de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les nouvelles initiatives du marché, la présence régionale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises par rapport au marché.

Français Certains des principaux acteurs du marché opérant sur le marché de l'amylose à transthyrétine héréditaire au Moyen-Orient et en Afrique sont Pfizer Inc, GE HealthCare, Siemens Healthcare GmbH, Koninklijke Philips NV, CANON MEDICAL SYSTEMS CORPORATION, Neusoft Corporation, NIHON KOHDEN CORPORATION., Shimadzu Corporation, Alnylam Pharmaceuticals, Inc., SCHILLER, Novo Nordisk A/S, FONAR Corp. et MinFound Medical Systems Co., entre autres.

SKU-70219